<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Stickel F</dc:creator>
  <dc:creator>Seitz HK</dc:creator>
  <dc:date>2010</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">Severe alcoholic steatohepatitis has a poor prognosis and is characterized by jaundice and signs of liver failure. Its incidence is unknown, but prevalence is around 20% in cohorts of alcoholics undergoing liver biopsy. Diagnosis is established with elevated liver transaminases, neutrophil counts, serum bilirubin, and impaired coagulation and a history of excessive alcohol consumption, and exclusion of other etiologies. Histology is helpful but not mandatory. Prognostic scores include the Maddrey's discriminant function, the model of end-stage liver disease, and the Glasgow Alcoholic Hepatitis Score. Pathophysiology involves hepatic fat storage, increased hepatic uptake of gut-derived endotoxins triggering Kupffer cell activation and release of proinflammatory triggers, induction of cytochrome P4502E1 producing toxic acetaldehyde and reactive oxygen species, and ethanol-mediated hyperhomocysteinemia causing endoplasmic reticulum stress. Treatment includes abstinence, enteral nutrition, corticosteroids, and possibly pentoxifylline. A debate is ongoing whether certain patients with severe alcoholic steatohepatitis could be eligible for liver transplantation.</dc:description>
  <dc:identifier>https://sonar.ch/global/documents/115923</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bpg.2010.07.003</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/20955970</dc:relation>
  <dc:source>Best practice &amp; research. Clinical gastroenterology. - 2010</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Cytochrome P-450 CYP2E1</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Enteral Nutrition</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Fatty Liver, Alcoholic</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Glucocorticoids</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Health Status Indicators</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Lipid Peroxidation</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Liver</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Liver Transplantation</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Prognosis</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Tumor Necrosis Factor-alpha</dc:subject>
  <dc:title xmlns:ns12="xml" ns12:lang="en">Alcoholic steatohepatitis.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
